SILO PHARMA, INC. Increase (Decrease) in Contract with Customer, Liability
SILO PHARMA, INC. (SILO) reported Increase (Decrease) in Contract with Customer, Liability of -$18.03 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-13
- SILO PHARMA, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$1.00.
- SILO PHARMA, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$18.02K.
- SILO PHARMA, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$18.03K.
- SILO PHARMA, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$18.02K.
- SILO PHARMA, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was -$72.10K.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$18.03K 10-Q · filed 2026-08-13 | -$36.05K derived: sum of 3 quarters · filed 2026-08-13 | -$54.08K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$18.02K 10-Q · filed 2026-05-14 | -$36.05K derived: sum of 2 quarters · filed 2026-05-14 | -$54.08K derived: sum of 3 quarters · filed 2026-05-14 | -$72.10K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$18.03K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | -$36.05K derived: sum of 2 quarters · filed 2026-04-14 | -$54.08K derived: sum of 3 quarters · filed 2026-08-13 | -$72.10K POS AM · filed 2026-04-14 |
| 2025-09-30 | -$18.02K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$36.05K derived: sum of 2 quarters · filed 2026-08-13 | -$54.08K 10-Q · filed 2025-11-13 | -$72.10K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$18.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$36.05K 10-Q · filed 2026-08-13 | -$54.08K derived: sum of 3 quarters · filed 2026-08-13 | -$72.10K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$18.03K 10-Q · filed 2026-05-14 | -$36.05K derived: sum of 2 quarters · filed 2026-05-14 | -$54.08K derived: sum of 3 quarters · filed 2026-05-14 | -$72.10K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$18.03K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | -$36.05K derived: sum of 2 quarters · filed 2026-04-14 | -$54.08K derived: sum of 3 quarters · filed 2026-04-14 | -$72.10K POS AM · filed 2026-04-14 |
| 2024-09-30 | -$18.02K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$36.05K derived: sum of 2 quarters · filed 2025-11-13 | -$54.08K 10-Q · filed 2025-11-13 | -$72.10K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$18.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$36.05K 10-Q · filed 2025-08-13 | -$54.08K derived: sum of 3 quarters · filed 2025-08-13 | -$72.10K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$18.03K 10-Q · filed 2025-05-09 | -$36.05K derived: sum of 2 quarters · filed 2025-05-09 | -$54.08K derived: sum of 3 quarters · filed 2025-05-09 | |
| 2023-12-31 | -$18.03K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$36.05K derived: sum of 2 quarters · filed 2025-03-28 | -$72.10K 10-K · filed 2025-03-28 | |
| 2023-09-30 | -$18.02K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$54.08K 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | -$36.05K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |